Poynard, Thierry

List of all publications

Publishing since 1977 (Dinosaur)

2010

Eyraud D, Ben Menna M, Vaillant JC, Kitajima K, Lebray P, Pavie A, Poynard T, Coriat P, Hannoun L. Perioperative management of combined heart-liver transplantation in patients with cirrhosis, renal insufficiency, or pulmonary hypertension. Clin Transplant 2010
Baumgaertner I, Ratziu V, Vaillant JC, Hannoun L, Poynard T, André T. [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review.] Bulletin du cancer 2010
Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51;2
Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138;2
Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T. Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis. Gastroenterology 2010
Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol. Clin. Biol. 2010;34;1
Friedrich-Rust M, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J. Clin. Gastroenterol. 2010;44;1

2009

Poynard T, Munteanu M, Ngo Y, Ratziu V. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2009;30;11-12
Poynard T, Shiff E. Similarities and differences between REPEAT and EPIC3. Ann. Intern. Med. 2009;151;10
Poynard T, Massard J, Rudler M, Varaud A, Lebray P, Moussalli J, Munteanu M, Ngo Y, Thabut D, Benhamou Y, Ratziu V. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. Gastroenterol. Clin. Biol. 2009;33;10-11
Akhavan S, Schnuriger A, Lebray P, Benhamou Y, Poynard T, Thibault V. Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV. J. Infect. Dis. 2009;200;4
Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009;252;2
Ratziu V, Poynard T. [Nonalcoholic fatty liver disease: 30 years research changed NASH] Gastroenterol. Clin. Biol. 2009;33;8-9
Ingiliz P, Chhay KP, Munteanu M, Lebray P, Ngo Y, Roulot D, Benhamou Y, Thabut D, Ratziu V, Poynard T. Applicability and variability of liver stiffness measurements according to probe position. World J. Gastroenterol. 2009;15;27
Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O'Brien C, Nguyen TT, Jia J, Poynard T, Belanger B, Bao W, Naoumov NV. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 2009;51;1
Poynard T, Benhamou Y, Thabut D, Ratziu V. Liver biopsy: the best standard...when everything else fails. J. Hepatol. 2009;50;6
Munteanu M, Ngo Y, Ratziu V, Poynard T. The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests". Gastroenterol. Clin. Biol. 2009;33;5
Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136;5
Poynard T, Ratziu V. Prolonged therapy for hepatitis C with low-dose peginterferon. N. Engl. J. Med. 2009;360;11
Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J. Viral Hepat. 2009;16;3
Vanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, Poynard T, Perarnau JM, Piquet MA, Pageaux GP, Dharancy S, Silvain C, Hillaire S, Thiefin G, Vinel JP, Hillon P, Collin E, Mantion G, Miguet JP. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann. Intern. Med. 2009;150;3
Munteanu M, Lebray P, Massard J, Moussalli J, Varaut A, Ngo Y, Thabut D, Imbert-Bismut F, Benhamou Y, Ratziu V, Poynard T. Discordance between results of biomarkers of fibrosis shows that it is at least a "ménage à deux". Gastroenterol. Clin. Biol. 2009;33;2
Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombès A, Benhamou Y. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009;49;2
Imbert-Bismut F, Naveau S, Morra R, Munteanu M, Ratziu V, Abella A, Messous D, Thabut D, Benhamou Y, Poynard T. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption. Eur J Gastroenterol Hepatol 2009;21;1
Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49;1

2008

Lebray P, Varnous S, Charlotte F, Varaut A, Poynard T, Ratziu V. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008;48;6
Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Assessment of liver fibrosis: noninvasive means. Saudi J Gastroenterol 2008;14;4
Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol. Clin. Biol. 2008;32;6 Suppl 1
Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D, Messous D, Massard J, Lebray P, Moussalli J, Benhamou Y, Ratziu V. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Gastroenterol. Clin. Biol. 2008;32;6 Suppl 1
Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin. Gastroenterol. Hepatol. 2008;6;7
Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135;1
Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112;12
Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis 2008;17;2
Poynard T, Munteanu M, Ngo Y, Moussalli J, Lebray P, Thabut D, Benhamou Y, Ratziu V. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence. J. Viral Hepat. 2008;15;6
Wartelle-Bladou C, Rosenthal E, Ratziu V, De Lédinghen V, Lang JP, Poynard T. [Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse] Gastroenterol. Clin. Biol. 2008;32;3 Pt 2
de Lédinghen V, Poynard T, Wartelle C, Rosenthal E. [Non-invasive evaluation of liver fibrosis in hepatitis C] Gastroenterol. Clin. Biol. 2008;32;3 Pt 2
Morra R, Lebray P, Ingiliz P, Ngo Y, Munteanu M, Ratziu V, Poynard T. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology 2008;47;1
Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, Messous D, Bismut FI, Roulot D, Benhamou Y, Thabut D, Ratziu V. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS ONE 2008;3;12
Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Rousselot-Bonnefont D, Moussalli J, Ratziu V, Poynard T. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 2008;3;7
Ingiliz P, Valantin MA, Thibault V, Duvivier C, Dominguez S, Katlama C, Poynard T, Benhamou Y. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir. Ther. (Lond.) 2008;13;7
Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaux AS, Verkarre V, Bechade D, Poynard T, Hermine O, Cellier C. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J. Hepatol. 2008;48;1

2007

Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, Duhamel C, Lebrec D, Poynard T, Moreau R. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46;6
Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC, Tellier Z, Guichard C, Ogier-Denis E, Poynard T, Moreau R, Lebrec D. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology 2007;46;6
Rosenthal-Allieri MA, Tran A, Halfon P, Imbert-Bismut F, Munteanu M, Messous D, Peritore ML, Poynard T, Bernard A. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. Gastroenterol. Clin. Biol. 2007;31;10
Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, Ratziu V, Charlotte F, Thibault V, Imbert-Bismut F, Poynard T. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2007;26;6
Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, Kechagias S, Poynard T, Olsson R. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment. Pharmacol. Ther. 2007;26;6
Zarski JP, Bedossa P, Bronowicki JP, Doffoel M, Poynard T. [Non invasive markers using for the assessment of fibrosis in hepatitis C] Gastroenterol. Clin. Biol. 2007;31;8-9 Pt 3
Thabut D, Imbert-Bismut F, Cazals-Hatem D, Messous D, Muntenau M, Valla DC, Moreau R, Poynard T, Lebrec D. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment. Pharmacol. Ther. 2007;26;3
Myers RP, Messous D, Poynard T, Imbert-Bismut F. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can. J. Gastroenterol. 2007;21;5
Simon-Rudler M, Massard J, Bernard-Chabert B, DI Martino V, Ratziu V, Poynard T, Thabut D. Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study. Aliment. Pharmacol. Ther. 2007;25;8
Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109;7
Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, Buffet C, Poynard T, Capron D, Raabe JJ, Roulot D, Naveau S, Grange JD, Poupon RE, Poupon R, Serfaty L. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin. Gastroenterol. Hepatol. 2007;5;4
Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, Munteanu M, Messous D, Ratziu V, Benhamou Y, Bourlière M, De Ledinghen V. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment. Pharmacol. Ther. 2007;25;6
Ratziu V, Vispo M, Tahiri M, Bonyhay L, de Torres M, Bernhardt C, Poynard T, Lebray P. [Can metabolic steatohepatitis be treated?] Gastroenterol. Clin. Biol. 2007;31;3
Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J. Viral Hepat. 2007;14;2
Poynard T. [Is liver biopsy still useful?] Rev Med Interne 2007;28;2
Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment. Pharmacol. Ther. 2007;25;2
Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7
Prodanovic H, Cracco C, Massard J, Barrault C, Thabut D, Duguet A, Datry A, Derenne JP, Poynard T, Similowski T. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol 2007;7

2006

Abel M, Sène D, Pol S, Bourlière M, Poynard T, Charlotte F, Cacoub P, Caillat-Zucman S. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006;44;6
Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 2006;44;4
McHutchison J, Poynard T, Afdhal N. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin. Gastroenterol. Hepatol. 2006;4;10
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment. Pharmacol. Ther. 2006;24;4
Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec D, Poynard T. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J. Hepatol. 2006;44;6
Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am. J. Gastroenterol. 2006;101;6
Halfon P, Bourlière M, Pol S, Benhamou Y, Ouzan D, Rotily M, Khiri H, Renou C, Pénaranda G, Saadoun D, Thibault V, Serpaggi J, Varastet M, Tainturier MH, Poynard T, Cacoub P. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J. Viral Hepat. 2006;13;5
Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, Mercier F, Deny P, Landais P, Parvaz P, Trepo C. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J. Viral Hepat. 2006;13;4
Thabut D, Trabut JB, Massard J, Rudler M, Muntenau M, Messous D, Poynard T. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int. 2006;26;3
d'Arondel C, Munteanu M, Moussalli J, Thibault V, Naveau S, Simon A, Messous D, Morra R, Blot C, Poynard T. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. J. Viral Hepat. 2006;13;3
Lada O, Benhamou Y, Poynard T, Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J. Virol. 2006;80;6
Boige V, Taïeb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E, Mignard D, Poynard T, Ducreux M. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur. J. Cancer 2006;42;4
Poynard T, Munteanu M, Ngo Y, Torres M, Benhamou Y, Thabut D, Ratziu V. Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 2006;43;2
Amouretti M, Le Pen C, Gaudin AF, Bommelaer G, Frexinos J, Ruszniewski P, Poynard T, Maurel F, Priol G, El Hasnaoui A. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol. Clin. Biol. 2006;30;2
Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Métivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 2006;12;2
Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6
Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6
Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol 2006;5
Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment. Pharmacol. Ther. 2006;23;1
Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin AG, Fievet MH, Currie G, Chang CG, Biao L, Xiong S, Brosgart C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J. Hepatol. 2006;44;1
Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. Natural history and predictors of disease severity in chronic hepatitis C. J. Hepatol. 2006;44;1 Suppl

2005

Ratziu V, Heurtier A, Bonyhay L, Poynard T, Giral P. Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link. Aliment. Pharmacol. Ther. 2005;22 Suppl 2
Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129;4 $Link to A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.$
McIlroy D, Théodorou I, Ratziu V, Vidaud D, Pellet P, Debré P, Poynard T. FAS promoter polymorphisms correlate with activity grade in hepatitis C patients. Eur J Gastroenterol Hepatol 2005;17;10
Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P, Thibault V, Parvaz P, Munteanu M, Trepo C. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am. J. Gastroenterol. 2005;100;9
Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129;2
Poynard T. Management of treatment non responders in chronic hepatitis C. Med. J. Malaysia 2005;60 Suppl B
Poynard T. Management of patients coinfected by HCV and HIV. Med. J. Malaysia 2005;60 Suppl B
Poynard T. Surrogate markers for liver fibrosis. Med. J. Malaysia 2005;60 Suppl B
Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128;7
Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005;128;4
Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin. Gastroenterol. Hepatol. 2005;3;2
Poynard T, Ratziu V, Kim N, Deuffic-Burban S. Age and gender will survive to competing risks as fibrosis factors. Gastroenterology 2005;128;2
Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4
Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. Diagnosis and treatment of viral liver fibrosis. Saudi J Gastroenterol 2005;11;1
Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed? J. Hepatol. 2005;42;1

2004

Ratziu V, Poynard T. Long-term outcome improvement in patients with chronic hepatitis D treated with interferon alpha. Nature clinical practice. Gastroenterology & hepatology 2004;1;2
Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, Moussalli J, Thabut D, Buffet C, Poynard T. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004;40;6
Poynard T. Treatment of cirrhotic patients in the pegylated interferon era. Dig Liver Dis 2004;36 Suppl 3
Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO, Poynard T. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004;16;12
Poynard T. [The Fibrotest is an ethical choice because it is a cost-effective and anti-inflationistic test. Response to Jean Louis Payen and Jean Marie Combis] Gastroenterol. Clin. Biol. 2004;28;10 Pt 1
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3;1
Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, Piton A, Bonyhay L, Ratziu V, Hainque B, Poynard T. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol 2004;3;1
Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir. Ther. (Lond.) 2004;9;3
Bommelaer G, Poynard T, Le Pen C, Gaudin AF, Maurel F, Priol G, Amouretti M, Frexinos J, Ruszniewski P, El Hasnaoui A. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol. Clin. Biol. 2004;28;6-7 Pt 1
Thabut D, Ratziu V, Trabut JB, Poynard T. Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. Gut 2004;53;6
Le Pen C, Ruszniewski P, Gaudin AF, Amouretti M, Bommelaer G, Frexinos J, Poynard T, Maurel F, Priol G, Bertin C. The burden cost of French patients suffering from irritable bowel syndrome. Scand. J. Gastroenterol. 2004;39;4
Ratziu V, Imbert-Bismut F, Messous D, Poynard T. The elusiveness of "normal" ALT in fatty liver. Hepatology 2004;39;4
Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004;39;3
Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J. Hepatol. 2004;40;2
Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004;6;1
Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004;18;1
Alatrakchi N, Di Martino V, Thibault V, Benhamou Y, Katlama C, Poynard T, Autran B. Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS 2004;18;1
Poynard T. Treatment of hepatitis C virus: the first decade. Semin. Liver Dis. 2004;24 Suppl 2

2003

Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362;9401
Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362;9401
Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003;98;12
Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J. Hepatol. 2003;39;6
Ratziu V, Le Calvez S, Bonyhay L, Taieb J, Poynard T. [Hepatocellular carcinoma and non alcoholic steatohepatitis: are we looking at the tip of the iceberg?] Gastroenterol. Clin. Biol. 2003;27;10
Poynard T. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C. Gut 2003;52;10
Ratziu V, Saboury M, Poynard T. Worsening of steatosis and fibrosis progression. Gut 2003;52;9
Poynard T. [Should we have the courage to say no to systematic liver biopsy?] Gastroenterol. Clin. Biol. 2003;27;8-9
Ratziu V, Poynard T. [Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists] Gastroenterol. Clin. Biol. 2003;27;8-9
Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38;2
Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003;39;2
Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur. J. Intern. Med. 2003;14;4
Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38;1
Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J. Viral Hepat. 2003;10;3
Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, Poynard T. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003;37;5
Koretz RL, Poynard T. Truth is not determined by a majority vote. Gastroenterology 2003;124;4
Poynard T, Thabut D, Chryssostalis A, Taieb J, Ratziu V. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J. Hepatol. 2003;38;4
Thabut D, Ratziu V, Bernard-Chabert B, Poynard T, Benhamou Y, Thibault V. Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure. Gut 2003;52;4
Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003;17;5
Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 2003;38;3
Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J. Viral Hepat. 2003;10;2
de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003;2;1
Benhamou Y, Poynard T. Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J. Hepatol. 2003;39 Suppl 1
Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig. Dis. Sci. 2003;48;1
Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J. Viral Hepat. 2003;10;1
Cacoub P, Bourlière M, Hausfater P, Charlotte F, Khiri H, Toci S, Piette JC, Poynard T, Halfon P. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection. J. Viral Hepat. 2003;10;1
Golli L, Taïeb J, Boleslawski E, Charlotte F, Taboury J, di Martino V, Poynard T, Hannoun L. [Mucosa-associated lyphoid tissue hepatic lymphoma with low-grade malignancy associated with primary biliary cirrhosis] Gastroenterol. Clin. Biol. 2003;27;1

2002

Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Thabut D, Myers RP, Poynard T. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;1;1
Colombat M, Charlotte F, Ratziu V, Poynard T. Portal lymphocytic infiltrate in alcoholic liver disease. Hum. Pathol. 2002;33;12
Ratziu V, Nourani M, Poynard T. Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;123;6
Poynard T. [Do the interferons have an antifibrotic action? The hepatologist's point of view] Rev Med Interne 2002;23 Suppl 4
Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Péron JM, Vinel JP, Durand D, Izopet J, Poynard T, Duffaut M, Rostaing L. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002;123;5
McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123;4
Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, Trépo C. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002;36;4 Pt 1
Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am. J. Gastroenterol. 2002;97;9
Bruckert E, Giral P, Ratziu V, Poynard T, Chapman MJ, Opolon P, Turpin G. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. Metab. Clin. Exp. 2002;51;8
Lebray P, Benhamou Y, Pol S, Myers RP, Poynard T, Di Martino V. NNRTI-related or -unrelated hepatotoxicity? Hepatology 2002;36;2
Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, Charlotte F, Piette JC, Moussalli J. Fatigue in patients with chronic hepatitis C. J. Viral Hepat. 2002;9;4
Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J, Opolon P. Truth survival in clinical research: an evidence-based requiem? Ann. Intern. Med. 2002;136;12
Cacoub P, Ratziu V, Myers RP, Ghillani P, Piette JC, Moussalli J, Poynard T. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J. Hepatol. 2002;36;6
Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35;6
Ratziu V, Sayegh-Tainturier MH, Nourani M, Poynard T. [Pre-C mutations of the HBV] Gastroenterol. Clin. Biol. 2002;26;5
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122;5
Poynard T. Uses of error. Lancet 2002;359;9316
Dangles V, Lazar V, Validire P, Richon S, Wertheimer M, Laville V, Janneau JL, Barrois M, Bovin C, Poynard T, Vallancien G, Bellet D. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. Br. J. Cancer 2002;86;8
Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16;6
Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J. Hepatol. 2002;36;4
Myers RP, Regimbeau C, Moussalli J, Ratziu V, Di Martino V, Thabut D, Bernard B, Benhamou Y, Poynard T. [What are the indications for treatment of acute hepatitis C?] Gastroenterol. Clin. Biol. 2002;26 Spec No 2
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122;4
Taïeb J, Delarche C, Paradis V, Mathurin P, Grenier A, Crestani B, Dehoux M, Thabut D, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. J. Hepatol. 2002;36;3
Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J. Viral Hepat. 2002;9;2
Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J. Viral Hepat. 2002;9;2
McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35;3
Goulenok C, Bernard B, Cadranel JF, Thabut D, Di Martino V, Opolon P, Poynard T. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther. 2002;16;3
Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14;2
Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grangé JD, Valla D, Lebrec D. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50;1

2001

Thabut D, Thibault V, Benhamou Y, Bernard B, Aubron-Olivier C, Poynard T, Di Martino V. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. AIDS 2001;15;18
Bommelaer G, Bruley Des Varannes S, Fléjou JF, Matysiak T, Poynard T, Richard A, Slama A, Mégraud F. [CagA status and virulence of Helicobacter pylori strains. Results of a French multicentric prospective study] Gastroenterol. Clin. Biol. 2001;25;12
Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358;9283
Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34;2
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J. Hepatol. 2001;34;5
Neuman MG, Brenner DA, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, Garaud JJ, Poynard T, Katz GG, Cameron RG, Shear NH, Gao B, Takamatsu M, Yamauchi M, Ohata M, Saito S, Maeyama S, Uchikoshi T, Toda G, Kumagi T, Akbar SM, Abe M, Michitaka K, Horiike N, Onji M. Mechanisms of alcoholic liver disease: cytokines. Alcohol. Clin. Exp. Res. 2001;25;5 Suppl ISBRA
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357;9262
Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2001;15;3
Généreau T, Charlotte F, Fillet AM, Poynard T, Herson S, Di Martino V. [Cytomegalovirus hepatitis is never chronic and may hide another!] Rev Med Interne 2001;22;2
Thévenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J. Viral Hepat. 2001;8;1

2000

Mouquet C, Bernard B, Poynard T, Thibault V, Opolon P, Coriat P, Bitker MO. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplant. Proc. 2000;32;8
McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119;5
Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32;5
Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000;47;5
Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90;10
Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am. J. Gastroenterol. 2000;95;6
Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can. J. Gastroenterol. 2000;14;6
Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000;118;6
Poynard T, Ratziu V, Benhamou Y, Regimbeau C. [Treatment and prevention of hepatitis C] Rev Prat 2000;50;10
Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, Opolon P, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J. Hepatol. 2000;32;4
Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol 2000;14;2
Mathurin P, Thibault V, Kadidja K, Ganne-Carrié N, Moussalli J, El Younsi M, Di Martino V, Lunel F, Charlotte F, Vidaud M, Opolon P, Poynard T. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J. Viral Hepat. 2000;7;1
Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin. Liver Dis. 2000;20;1
Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Charpentier Y, Poynard T. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum. Pathol. 2000;31;1
Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31;1

1999

Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 1999;3;4
Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30;5
Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30;4
Deuffic S, Poynard T, Valleron AJ. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J. Viral Hepat. 1999;6;5
Poynard T, Daurat V, Chevret S, Moussalli J, Degos F, Bailly F, Borotto E, Buffet C, Bartolomei-Portal I, Richardet JP, Riachi G, Calmus Y, Bréchot C, Vidaud M, Olivi M, Bedossa P, Riffaud PC, Chastang C. A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group. J. Viral Hepat. 1999;6;5
Di Martino V, Ezenfis J, Benhamou Y, Bernard B, Opolon P, Bricaire F, Poynard T. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS 1999;13;11
Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, Opolon P, Nguyen DT, Golliot F, Piette JC, Huraux JM, Lunel F. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999;45;1
Calés P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, Abergel A, Bichard P, Raymond JM, Canva-Delcambre V, Vetter D, Valla D, Beauchant M, Hadengue A, Champigneulle B, Pascal JP, Poynard T, Lebrec D. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol 1999;11;7
Doffoël M, Wolf P, Portolani N, Vetter D, Boudjema K, Jaeck D, Poynard T. [Results and indications of liver transplantation in alcoholic cirrhosis] Gastroenterol. Clin. Biol. 1999;23;5 Pt 2
Imbert-Bismut F, Charlotte F, Turlin B, Khalil L, Piton A, Brissot P, Le Charpentier Y, Delattre J, Opolon P, Deugnier Y, Poynard T. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring. J. Clin. Pathol. 1999;52;6
González-Peralta RP, Galasso GJ, Poynard T, Schalm S, Thomas HC, Wright TL. Summary of the first international symposium on viral hepatitis. Antiviral Res. 1999;42;2
Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29;6
Poynard T, Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G, Messner M, Launois B, Samuel D, Cherqui D, Pageaux G, Bernard PH, Calmus Y, Zarski JP, Miguet JP, Chaput JC. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J. Hepatol. 1999;30;6
Naveau S, Borotto E, Giraud V, Bardou M, Aubert A, Lazizi Y, Capron F, Poynard T, Chaput JC. [Descriptive epidemiology of patients with alcoholic liver disease hospitalized in a hepato-gastroenterology service] Gastroenterol. Clin. Biol. 1999;23;5
Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29;5
Calès P, Castaing D, Grangé JD, Lebrec D, Lemoine O, Poynard T, Silvain C, Sogni P, Vinel JP, Vons C, Nouel O, Bourgeois N, Bernard B, Hadengue A. [Treatment of portal hypertension] Gastroenterol. Clin. Biol. 1999;23;3
Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116;2
Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29;1
Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. Effects of interferon therapy in "non responder" patients with chronic hepatitis C. J. Hepatol. 1999;31 Suppl 1
McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 1999;19 Suppl 1
Raymond JM, Marquis P, Bechade D, Smith D, Mathiex Fortunet H, Poynard T, Galmiche JP, Amouretti M. [Assessment of quality of life of patients with gastroesophageal reflux. Elaboration and validation of a specific questionnaire] Gastroenterol. Clin. Biol. 1999;23;1
Poynard T. [Role and limits of self-medication in the therapeutic strategy of gastroesophageal reflux in adults] Gastroenterol. Clin. Biol. 1999;23;1 Pt 2

1998

Mathurin P, Taïeb J, Poynard T. [Corticosteroid therapy in acute severe alcoholic hepatitis: the end of a controversy?] Gastroenterol. Clin. Biol. 1998;22;12
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998;352;9138
Poynard T, Moussalli J, Ratziu V, Thevenot T, Regimbeau C, Opolon P, Horsmans Y, Brenard R, Closon M, Fevery J, Hautekeete M. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Acta Gastroenterol. Belg. 1998;61;4
Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J. Viral Hepat. 1998;5;5
Desramé J, Mathurin P, Rozov R, Sabaté JM, Poynard T, Opolon P, Denis J. [Isolated ascites revealing a hypothyroidism. Study of 2 cases] Gastroenterol. Clin. Biol. 1998;22;8-9
Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998;59 Suppl 2
Cacoub P, Musset L, Hausfater P, Ghillani P, Fabiani FL, Charlotte F, Angevin E, Opolon P, Poynard T, Piette JC, Autran B. No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc Group. Clin. Exp. Immunol. 1998;113;1
Taïeb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 1998;351;9120
Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology 1998;27;5
Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998;27;5
Mathurin P, Ganne-Carrié N, Poynard T, Trinchet JC. [Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis] Gastroenterol. Clin. Biol. 1998;22;3
Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27;3
Bièche I, Lazar V, Noguès C, Poynard T, Giovangrandi Y, Bellet D, Lidereau R, Vidaud M. Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. Clin. Cancer Res. 1998;4;3
Moussalli J, Opolon P, Poynard T. Management of hepatitis C. J. Viral Hepat. 1998;5;2
Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment. Pharmacol. Ther. 1998;12;2
Calès P, Henrion J, Pascal JP, Valla D, Lapuelle J, Lunel F, Poynard T, Doffoël M. [Proposition of a code of ethics in clinical research] Gastroenterol. Clin. Biol. 1998;22;2
Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 1998;12;2
Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351;9097

1997

Thevenot T, Mathurin P, Martinez F, Moussalli J, Poynard T, Opolon P, Chosidow O. Acute hepatitis during hypersensitivity syndrome due to midecamycin. Eur J Gastroenterol Hepatol 1997;9;12
Thevenot T, Mathurin P, Moussalli J, Perrin M, Plassart F, Blot C, Opolon P, Poynard T. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. J. Viral Hepat. 1997;4;4
Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997;26;1
Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, Opolon P, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J. Clin. Pathol. 1997;50;5
Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J. Viral Hepat. 1997;4;3
Auperin A, Pignon JP, Poynard T. Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology. Aliment. Pharmacol. Ther. 1997;11;2
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349;9055
Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J. Hepatol. 1997;26;2
Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997;25;1
Poynard T, Ottignon Y, Pauphilet C, Agostini H. [Evaluation by a randomized trial of the usefulness of endoscopy after treatment of a flare-up of non-severe esophagitis] Gastroenterol. Clin. Biol. 1997;21;6-7
Poynard T. [Should hepatitis C be treated? What are indications of treatment in acute hepatitis C?] Gastroenterol. Clin. Biol. 1997;21;1 Pt 2
Tordjman G, Bernard B, Chigot JP, Poynard T, Opolon P. [Recurrent lower digestive hemorrhage in young adults: a surgical indication] Gastroenterol. Clin. Biol. 1997;21;3
Denié C, Poynard T, Gadano A, Vachiery F, Soupison T, Elman A, Valla D, Moreau R, Lebrec D. [Influence of anemia on hemodynamic changes in patients with cirrhosis] Gastroenterol. Clin. Biol. 1997;21;1

1996

Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP. Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig. Dis. Sci. 1996;41;12 Suppl
Paradis V, Mathurin P, Laurent A, Charlotte F, Vidaud M, Poynard T, Hoang C, Opolon P, Bedossa P. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J. Clin. Pathol. 1996;49;12
Mathurin P, Cadranel JF, Bouraya D, Bronstein JA, Collot G, Devergie B, Poynard T, Opolon P. Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. Eur J Gastroenterol Hepatol 1996;8;11
Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med. 1996;125;9
Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24;4
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24;2
Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J. Hepatol. 1996;25;2 $Link to Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists.$
Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110;6
Ghoumari AM, Rixe O, Yarovoi SV, Zerrouqi A, Mouawad R, Poynard T, Opolon P, Khayat D, Soubrane C. Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. Gene Ther. 1996;3;6
Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 1996;23;5
Mathurin P, Vidaud D, Vidaud M, Bedossa P, Paradis V, Ratziu V, Chaput JC, Poynard T. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology 1996;23;1
Borie DC, Poynard T, Hannoun L. [Xenotransplantation in man. 2: Control of rejection and application to xenotransplantation of the swine liver in man] Gastroenterol. Clin. Biol. 1996;20;11
Borie DC, Poynard T, Hannoun L. [Xenotransplantation in man. 1: Immunology of xenogenic graft rejection] Gastroenterol. Clin. Biol. 1996;20;11
Maillard MF, Poynard T, Dubreuil P, Agostini H, Hautecoeur B, Pillot J, Chaput JC. [Prevalence of serum anti-hepatitis C virus antibodies and risk factors of contamination in the personnel of a hospital in the Paris region. A prospective survey] Gastroenterol. Clin. Biol. 1996;20;12

1995

Carrère MO, Auquier P, Poynard T, Sambuc R. [Medico-economic aspects of the treatment of duodenal ulcer: from antisecretory treatment to eradication of Helicobacter pylori] Gastroenterol. Clin. Biol. 1995;19;12
Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7;7
Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N. Engl. J. Med. 1995;332;22
Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995;21;3
Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995;345;8946
Poynard T, Lonjon I, Mathurin P, Abella A, Musset D, Bedossa P, Aubert A, Naveau S, Chaput JC. Prevalence of cholelithiasis according to alcoholic liver disease: a possible role of apolipoproteins AI and AII. Alcohol. Clin. Exp. Res. 1995;19;1
Pillot J, Poynard T, Elias A, Maillard J, Lazizi Y, Brancer M, Dubreuil P, Budkowska A, Chaput JC. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. Vaccine 1995;13;3
Poynard T, Bedossa P, Mathurin P, Ratziu V, Paradis V. Apolipoprotein A1 and hepatic fibrosis. J. Hepatol. 1995;22;2 Suppl

1994

Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 1994;20;6
Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J. Intern. Med. 1994;236;6
Terris B, Bedossa P, Poynard T. No effect of neutralizing antibody to TGF-beta 1 in acute CC14-induced liver fibrogenesis. J. Hepatol. 1994;21;6
Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig. Dis. Sci. 1994;39;11
Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 1994;8;5
Poynard T, Barthelemy P, Fratte S, Boudjema K, Doffoel M, Vanlemmens C, Miguet JP, Mantion G, Messner M, Launois B. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. Lancet 1994;344;8921
Brocker P, Vellas B, Albarede JL, Poynard T. A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing 1994;23;4
Holstege A, Bedossa P, Poynard T, Kollinger M, Chaput JC, Houglum K, Chojkier M. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis. Hepatology 1994;19;2

1993

Pignon JP, Poynard T. [Meta-analysis of therapeutic trials. Principles, methods and critical reading] Rev Prat 1993;43;18
Poynard T. Relapse rate of patients after healing of oesophagitis--a prospective study of alginate as self-care treatment for 6 months. French Co-operative Study Group. Aliment. Pharmacol. Ther. 1993;7;4
Smadja C, Ratziu V, Poynard T, Chaput JC, Franco D. Laparoscopic treatment without cholecystectomy for gallbladder perforation after liver biopsy. J. Hepatol. 1993;18;3
Bedossa P, Poynard T, Mathurin P, Lemaigre G, Chaput JC. Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut 1993;34;2 Suppl

1992

Darmoni SJ, Poynard T. Computer-aided decision support in hepatology. Scand. J. Gastroenterol. 1992;27;10
Ink O, Martin T, Poynard T, Reville M, Anciaux ML, Lenoir C, Marill JL, Labadie H, Masliah C, Perrin D. Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. Hepatology 1992;16;4
Naveau S, Chaput JC, Bedossa P, Poynard T, Pauphilet C, Ink O, Houdayer C, Aubert A. Cirrhosis as an independent risk factor for colonic adenomas. Gut 1992;33;4
Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N. Engl. J. Med. 1992;326;8
Budkowska A, Dubreuil P, Poynard T, Marcellin P, Loriot MA, Maillard P, Pillot J. Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection. Hepatology 1992;15;1
Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann. Intern. Med. 1992;116;1
Naveau S, Barritault L, Zourabichvili O, Champagne C, Prieur G, Limoge A, Poynard T, Chaput JC. [Analgesic effect of transcutaneous cranial electrostimulation in patients treated by Nd:YAG laser for cancer of the rectum. A double-blind randomized trial] Gastroenterol. Clin. Biol. 1992;16;1

1991

Naveau S, Bedossa P, Poynard T, Mory B, Chaput JC. Portal hypertensive colopathy. A new entity. Dig. Dis. Sci. 1991;36;12
Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N. Engl. J. Med. 1991;324;22
Poynard T, Aubert A, Lazizi Y, Bedossa P, Hamelin B, Terris B, Naveau S, Dubreuil P, Pillot J, Chaput JC. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991;13;5
Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991;100;5 Pt 1
Poynard T, Bedossa P, Mathurin P, Naveau S, Delfraissy JF, Lemaigre G, Chaput JC. Efficacy of long term recombinant interferon-alfa in patients with chronic hepatitis C. A clinical, biological, histological and immunohistological study. Gastroenterol. Clin. Biol. 1991;15;8-9
Pignon JP, Poynard T. [Meta-analysis of clinical trials] Gastroenterol. Clin. Biol. 1991;15;3
Poynard T, Pignon JP. [Meta-analysis: a tool for clinical Hepato-Gastroenterology] Gastroenterol. Clin. Biol. 1991;15;3
Paraf F, Brenot F, Poynard T, Petitpretz P, Bedossa P, Chaput J, Duroux P. [Disseminated Mycobacterium avium intracellulare infection revealed by hepatomegaly and cholestasis in acquired immunodeficiency syndrome] Gastroenterol. Clin. Biol. 1991;15;1
Ratziu V, Poynard T, Sabah H, Naveau S, Chaput JC. [Hepatotoxicity of moxisylyte chlorhydrate: a new case] Gastroenterol. Clin. Biol. 1991;15;12
Naveau S, Perrier C, Mory B, Poynard T, Chaput JC. [Endoscopic hemostasis for hemorrhagic gastroduodenal ulcer. Meta-analysis of randomized clinical trials] Gastroenterol. Clin. Biol. 1991;15;8-9
Filoche B, Carteret E, Couzigou B, Guerder A, Lombard M, Pouts-Lajus P, Sans J, Poynard T, Juif-Bielsky MC, Richard-Berthe C. [Randomized double-blind trial with a liquid suspension of alginate for the treatment of pyrosis] Gastroenterol. Clin. Biol. 1991;15;12

1990

Budkowska A, Dubreuil P, Maillard P, Poynard T, Pillot J. A biphasic pattern of anti-pre-S responses in acute hepatitis B virus infection. Hepatology 1990;12;6
Poynard T, Pauphilet C. [Alcoholic liver diseases excluding cirrhosis. Diagnosis, course and prognosis, principles of the treatment] Rev Prat 1990;40;26
Poynard T, Bedossa P, Jais P, Abella A, Naveau S, Aubert A, Lemaigre G, Chaput JC. Serum apolipoprotein A-I in alcoholic patients with chronic calcifying pancreatitis. Pancreas 1990;5;5
Poynard T, Cales P, Pasta L, Pagliaro L, Ideo G, Lebrec D. beta-blockers and variceal haemorrhage. Lancet 1990;336;8713
Naveau S, Aubert A, Poynard T, Chaput JC. Long-term results of treatment of vascular malformations of the gastrointestinal tract by neodymium YAG laser photocoagulation. Dig. Dis. Sci. 1990;35;7
Poynard T. Apolipoproteinemia A and alpha-fetoprotein in the diagnosis of hepatocellular carcinoma and cirrhosis: several interpretations. Hepatology 1990;11;5
Pol S, Poynard T, Bedossa P, Naveau S, Aubert A, Chaput JC. Diagnostic value of serum gamma-glutamyl-transferase activity and mean corpuscular volume in alcoholic patients with or without cirrhosis. Alcohol. Clin. Exp. Res. 1990;14;2
Bedossa P, Poynard T, Bacci J, Naveau S, Lemaigre G, Chaput JC, Martin E. Expression of histocompatibility antigens and characterization of the lymphocyte infiltrate in hyperplastic polyps of the large bowel. Hum. Pathol. 1990;21;3
Naveau S, Chiesa A, Poynard T, Chaput JC. Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer. Parameters affecting long-term outcome. Dig. Dis. Sci. 1990;35;3
Poynard T. [Critical study of gastroduodenal complications of corticotherapy] Rev Prat 1990;40;6
Poynard T. [Modesty, uncertainty and pragmatism] Gastroenterol. Clin. Biol. 1990;14;6-7
Poynard T, Klepping C, Audigier JC, Barthelemy C, Bel A, Delmont J, Fournet J, Gaucher P, Rachail M. Randomized double-blind clinical trial of aluminum phosphate versus ranitidine in the acute treatment of duodenal ulcer. Digestion 1990;47;2
Bedossa P, Ngendayo L, Hervé P, Rain B, Poynard T, Simonneau G. [Nodular regenerative hyperplasia and pulmonary arterial hypertension] Gastroenterol. Clin. Biol. 1990;14;11
Biour M, Davy JM, Poynard T, Lévy VG. [Is fluindione hepatotoxic?] Gastroenterol. Clin. Biol. 1990;14;10
Naveau S, Mory B, Poynard T, Chaput JC. [Randomized therapeutic trials in intestinal functional disorders] Gastroenterol. Clin. Biol. 1990;14;5 ( Pt 2)
Mory B, Poynard T, Naveau S, Chaput JC. [Epidemiology and methodology of randomized therapeutic trials in patients with intestinal functional disorders] Gastroenterol. Clin. Biol. 1990;14;5 ( Pt 2)
Poynard T, Lemann M, Darmoni SJ. [What to expect from expert systems for the diagnosis of functional bowel disorders] Gastroenterol. Clin. Biol. 1990;14;5 ( Pt 2)
Poynard T. [Short-term severity factors of digestive hemorrhage caused by portal hypertension in patients with cirrhosis] Gastroenterol. Clin. Biol. 1990;14;1 ( Pt 2)
Pateron D, Naveau S, Brivet F, Bedossa P, Poynard T, Chaput JC. [Acute tuberculous pancreatitis in a patient with acquired immunodeficiency syndrome] Gastroenterol. Clin. Biol. 1990;14;1
Sharma MD, Maillard P, Vrati S, Mukherjee R, Rajagopalan MS, Poynard T, Talwar GP, Pillot J. Serial passage of west-European sporadic non-A non-B hepatitis in rhesus monkeys by inoculation with fecal extracts. J. Med. Virol. 1990;30;1

1989

Bedossa P, Poynard T, Abella A, Aubert A, Pignon JP, Naveau S, Leluc R, Lemaigre G, Martin ED, Chaput JC. Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients. Alcohol. Clin. Exp. Res. 1989;13;6
Poynard T, Bedossa P, Naveau S, Lemaigre G, Martin ED, Chaput JC. Perisinusoidal cells (Ito-cells) enlargement in a family with myotonic dystrophy. Liver 1989;9;5
Paraf F, Naveau S, Zourabichvili O, Poynard T, Chaput JC. Endoscopic laser therapy for duodenal villous adenoma. Dig. Dis. Sci. 1989;34;9
Bedossa P, Poynard T, Abella A, Paraf F, Lemaigre G, Martin E. Localization of apolipoprotein A-I and apolipoprotein A-II in human atherosclerotic arteries. Arch. Pathol. Lab. Med. 1989;113;7
Poynard T. [The liver under top protection?] Gastroenterol. Clin. Biol. 1989;13;6-7
Naveau S, Bedossa P, Mallet L, Turner L, Poynard T, Andréani T, Chaput JC. Successful ablation of a large fibrovascular polyp of the esophagus by endoscopic Nd:YAG laser therapy. Gastrointest. Endosc. 1989;35;3
Naveau S, Poynard T, Zourabichvili O, Poitrine A, Chaput JC. A randomized study of a coaxial fiber versus a naked fiber for endoscopic Nd:YAG laser therapy of esophageal and rectal tumors. Gastrointest. Endosc. 1989;35;3
Naveau S, Poynard T, Pauphilet C, Aubert A, Chaput JC. Rectal and colonic varices in cirrhosis. Lancet 1989;1;8638
Poynard T, Pignon JP, Mory B, Naveau S, Chaput JC. Methodological problems of randomized clinical trials in the treatment of duodenal ulcer, "gastritis" and Campylobacter pylori infection. Gastroenterol. Clin. Biol. 1989;13;1 Pt 1
Lebrec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron JP, Poupon R, Bouvry M, Rueff B, Benhamou JP. A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. Drugs 1989;37 Suppl 2

1988

Poynard T, Aubert A, Naveau S, Lemman M, Chaput JC. [Sclerotherapy of esophageal varices using ethanol in combination with propranolol: clinical study of 30 patients] Gastroenterol. Clin. Biol. 1988;12;12
Poynard T, Tournade JM, Alberola B, Pappo M. [Semiology of gastroduodenal ulcer proved by endoscopy: epidemiological analysis of 1,800 cases] Gastroenterol. Clin. Biol. 1988;12;8-9
Lebrec D, Poynard T, Capron JP, Hillon P, Geoffroy P, Roulot D, Chaput JC, Rueff B, Benhamou JP. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J. Hepatol. 1988;7;1
Poynard T, Pignon JP, Naveau S, Chaput JC. Prognostic evaluation in cirrhosis. Hepatology 1988;8;4
Poynard T. [Do digestive complications of corticotherapy exist?] Presse Med 1988;17;25
Geffriaud C, Poynard T, Delfraissy JF, Bedossa P, Naveau S, Bourée P, Dubreuil P, Chaput JC. [Hepatic involvement in HIV 1 virus infection] Gastroenterol. Clin. Biol. 1988;12;5
Poynard T. [Evaluation of the methodological quality of randomized therapeutic trials] Presse Med 1988;17;7
Bedossa P, Poynard T, Chaput JC, Martin E. A decade of Campylobacter pylori. Lancet 1988;1;8582
Bedossa P, Poynard T, Naveau S, Martin ED, Agostini H, Chaput JC. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol. Clin. Exp. Res. 1988;12;1

1987

Darmoni SJ, Poynard T, Membrado M, Parigot D, Naveau S, Chaput JC. [Development of an expert system as a teaching aid in the serological diagnosis of acute viral hepatitis] Presse Med 1987;16;38
Paraf F, Poynard T, Bedossa P, Gayral F, Naveau S, Pignon JP, Lemaigre G, Chaput JC. Adenocarcinoma of the Vater's ampulla and von Recklinghausen disease. Ann. Intern. Med. 1987;107;5
Pignon JP, Poynard T, Naveau S, Sebag G, Chaput JC. [Treatment of gastroesophageal reflux: analysis of randomized double-blind trials] Gastroenterol. Clin. Biol. 1987;11;10
Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J. Hepatol. 1987;5;2
Aubert A, Naveau S, Poynard T, Maillard MF, Pillot J, Chaput JC. [Evaluation of hepatitis B vaccination in a Paris hospital personnel. 386 subjects] Presse Med 1987;16;27
Pignon JP, Baraona E, Poynard T, Chaput JC, Lieber CS. [Serum lipoproteins and alcoholic diseases of the liver] Gastroenterol. Clin. Biol. 1987;11;6-7
Naveau S, Zourabichvili O, Poitrine A, Houdayer C, Poynard T, Chaput JC. [Palliative treatment of cancers of the esophagus and cardia with neodymium YAG laser: short-term results and multidimensional analysis of factors related to functional improvement and tumor destruction] Gastroenterol. Clin. Biol. 1987;11;5
Poynard T, Lebrec D, Hillon P, Sayegh R, Bernuau J, Naveau S, Chaput JC, Klepping C, Rueff B, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987;7;3
Poynard T, Delfraissy JF, Naveau S, Dubreuil P, Gut JP, Raskine L, Grangeot-Keros L, Pillot J, Chaput JC. Reduction of the observed prevalence of so-called non-A non-B hepatitis using sensitive markers of HBV and herpes viruses infections. Gastroenterol. Clin. Biol. 1987;11;4
Poynard T, Degott C, Munoz C, Lebrec D. Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis. Effect of acute alcoholic hepatitis on portal hypertension. Dig. Dis. Sci. 1987;32;4

1986

Naveau S, Poynard T, Zourabichvili O, Poitrine A, Chaput JC. Gastric phytobezoar destruction by Nd:YAG laser therapy. Gastrointest. Endosc. 1986;32;6
Naveau S, Roulot D, Cartier I, Blanchard A, Poynard T, Drouhet E, Chaput JC. [Ulcerative colitis caused by Histoplasma capsulatum in a patient with the acquired immunodeficiency syndrome] Gastroenterol. Clin. Biol. 1986;10;11
Darmoni SJ, Lindenbaum A, Poynard T, Naveau S, Chaput JC. [Lipid peroxidation, free radicals and alcoholic liver diseases] Gastroenterol. Clin. Biol. 1986;10;11
Poynard T, Abella A, Pignon JP, Naveau S, Leluc R, Chaput JC. Apolipoprotein AI and alcoholic liver disease. Hepatology 1986;6;6
Naveau S, Roulot D, Zourabichvili O, Poitrine A, Poynard T, Chaput JC. [Palliative treatment of adenocarcinoma of the rectum by Nd-YAG laser. Immediate and long-term results. Study of factors related to the initial destruction of the tumor] Gastroenterol. Clin. Biol. 1986;10;10
Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, Degott C, Bezeaud A, Rueff B, Benhamou JP. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6;4
Poynard T, Mignon M, Accary JP, Bonfils S. Sensitivity, specificity and predictive values of the secretin infusion test in the diagnosis of gastrinoma. Gastroenterol. Clin. Biol. 1986;10;6-7
Pignon JP, Poynard T, Naveau S, Marteau P, Zourabichvili O, Chaput JC. [Multidimensional analysis by Cox's model of the survival of patients with alcoholic cirrhosis] Gastroenterol. Clin. Biol. 1986;10;6-7
Poynard T. [Value of multidimensional analysis by Cox's model] Gastroenterol. Clin. Biol. 1986;10;6-7
Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986;90;4
Millat B, Zazzo JF, Poynard T. [Randomized therapeutic trials in the treatment of acute pancreatitis] Gastroenterol. Clin. Biol. 1986;10;4
Naveau S, Pelletier G, Poynard T, Attali P, Poitrine A, Buffet C, Etienne JP, Chaput JC. A randomized clinical trial of supplementary parenteral nutrition in jaundiced alcoholic cirrhotic patients. Hepatology 1986;6;2

1985

Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985;6;4
Naveau S, Poynard T, Abella A, Pignon JP, Poitrine A, Agostini H, Zourabichvili O, Chaput JC. Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients. Hepatology 1985;5;5
Chaput JC, Poynard T, Naveau S, Penso D, Durrmeyer O, Suplisson D. Psoriasis, alcohol, and liver disease. Br Med J (Clin Res Ed) 1985;291;6487
Naveau S, Delfraissy JF, Poitrine A, Poynard T, Chaput JC. [Simultaneous detection of IgM antibodies against the hepatitis A virus and the viral capsid antigen of Epstein-Barr virus in acute hepatitis] Gastroenterol. Clin. Biol. 1985;9;2
Conn HO, Poynard T. Adrenocorticosteroid administration and peptic ulcer: a critical analysis. J Chronic Dis 1985;38;6

1984

Naveau S, Poynard T, Poitrine A, Chaput JC. [Intestinal function disorders. Review of the literature from 1977 to 1983] Gastroenterol. Clin. Biol. 1984;8;12
Le Bourgeois PC, Poynard T, Modai J, Marche C, Avril MF, Chaput JC. [Peri-anal ulceration. Tuberculosis should not be overlooked] Presse Med 1984;13;41
Naveau S, Poitrine A, Poynard T, Thuvignon E, Chaput JC. [Palliative treatment of cancers of the esophagus and cardia with YAG neodymium laser. (Preliminary noncontrolled trial)] Gastroenterol. Clin. Biol. 1984;8;6-7
Lebrec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron JP, Poupon R, Bouvry M, Rueff B, Benhamou JP. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984;4;3
Poynard T. [Hepatic involvement in sexually transmissible diseases] Presse Med 1984;13;18
Chaput JC, Poitrine A, Naveau S, Poynard T, Pillot J. Hepatitis b vaccine: a diagnostic test for previous hepatitis B virus infection? Lancet 1984;1;8382
Valla D, Poynard T, Bercoff E, Bataille C, Goldfarb G, Lebrec D. [Systemic circulatory hyperkinetic syndrome in patients with cirrhosis. Relation with hepatocellular failure and portal hypertension] Gastroenterol. Clin. Biol. 1984;8;4
Poynard T, Zourabichvili O, Hilpert G, Naveau S, Poitrine A, Benatar C, Chaput JC. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984;4;2
Conn HO, Poynard T. Adrenocorticosteroid therapy and peptic-ulcer disease. N. Engl. J. Med. 1984;310;3

1983

Poynard T, Poitrine A, Naveau S, Gaudineau MD, Trébuchet L, Chaput JC. [Analysis of factors related to length of stay in the hospital in a hepato-gastroenterology unit] Gastroenterol. Clin. Biol. 1983;7;12
Dorf G, Poynard T. [Controlled study of pentaerythritol in the treatment of subjects with functional intestinal disorders of the constipation type] Therapie 1983;38;4
Poynard T, Naveau S, Poitrine A, Lebourgeois P, Hilpert G, Chaput JC. Recurrent bleeding and propranolol? Dig. Dis. Sci. 1983;28;7
Poynard T, Mary JY, Chaput JC. [Value of multidimensional analysis in clinical research] Rev Prat 1983;33;21
Poynard T. [Evaluation of diagnostic mean values: the pitfalls] Rev Prat 1983;33;19
Poynard T. [Evaluation of diagnostic mean values: informational indices] Rev Prat 1983;33;19
Lacaine F, Poynard T. [Medical statistics used by the practitioner: hazard or necessity?] Rev Prat 1983;33;19
Naveau S, Poynard T, Fréville C, Poitrine A, Préaux N, Chaput JC. [Effect of guar gum on absorption of ethanol in man] Gastroenterol. Clin. Biol. 1983;7;4
Poitrine A, Poynard T, Naveau S, Hilpert G, Chaput JC. [A new fatal case of hepatitis caused by clometacin] Gastroenterol. Clin. Biol. 1983;7;1

1982

Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. Liver 1982;2;4
Poynard T, Slama G, Tchobroutsky G. Reduction of post-prandial insulin needs by pectin as assessed by the artificial pancreas in insulin-dependent diabetics. Diabete Metab 1982;8;3
Poynard T, Nataf C, Messing B, Modigliani R, Lecompte T, Nicolas P, Dray F, Ferme C. Secretory diarrhea and prostaglandin D2 overproduction in systemic mastocytosis. N. Engl. J. Med. 1982;307;3
Gin H, Slama G, Weissbrodt P, Poynard T, Vexiau P, Klein JC, Tchobroutsky G. Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 1982;23;1
Poynard T, Mazeron MC, Vacherot B, Florent C, Nataf C, Scieux C, Colimon R, Abadia R, Pérol Y. [Chlamydia trachomatis perihepatitis (author's transl)] Gastroenterol. Clin. Biol. 1982;6;4
Poynard T. [Liver and sexual freedom (author's transl)] Gastroenterol. Clin. Biol. 1982;6;4
Poynard T, Chaput JC, Etienne JP. Relations between effectiveness of a diagnostic test, prevalence of the disease, and percentages of uninterpretable results. An example in the diagnosis of jaundice. Med Decis Making 1982;2;3

1981

Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N. Engl. J. Med. 1981;305;23
Poynard T, Girard-Pipau F, Pérol Y. [Virus, Crohn's disease, ulcerative colitis and non-specific enterocolitis] Gastroenterol. Clin. Biol. 1981;5;5
Beaugrand M, Poynard T, Callard P, Ferrier JP, Bernades P, Molas G, Ferchal F, Perol Y. [Search of a cytomegalovirus infection during pseudo-membranous colitis. 6 cases (author's transl)] Nouv Presse Med 1981;10;15
Poynard T, Chaput JC, Mary JY, Buffet C, Scolaro JM, Labayle D, Etienne JP. Upper digestive tract hemorrhage in cirrhotic patients. Contribution of multidimensional analysis to the study of variables related to the cause of the hemorrhage. Dig. Dis. Sci. 1981;26;3
Martin F, Poynard T, Ribet A, Escourrou J, Delpu J, Klepping C, Bernier JJ, Soullard J, Marti R, Nisard A, Bader JP, Sarles H, Sahel J, Bonfils S, Vilotte J, Grenier J, Loygue J, Flamant R. A cooperative study on the detection of colorectal cancer and polyps in France. Cancer Detect. Prev. 1981;4;1-4

1980

Poynard T, Chaput JC, Mary JY, Scolaro M, Buffet C, Etienne JP. [Factors related to 30th day mortality in upper digestive tract hemorrhage in cirrhotic patients (author's transl)] Gastroenterol. Clin. Biol. 1980;4;10
Vitaux J, Labayle D, Poynard T, Challas J, Chaput JC. [Comparative effects of lemon and apple pectins on oral glucose tolerance test in patients after gastric surgery] Nouv Presse Med 1980;9;24
Slama G, Klein JC, Garrel D, Poynard T, Nguyen Phoc Buu K, Van Halle B, Collas C, Delage A, Tchobroutsky G. [New technics of insulin adminstration: experience of the Hotel-Dieu] Journ Annu Diabetol Hotel Dieu 1980
Buffet C, Chaput JC, Labayle D, Poynard T, Etienne JP. [Emergency fiberscopy in digestive hemorrhages in cirrhosis patients. Critical reflections] Nouv Presse Med 1980;9;19
Poynard T, Slama G, Delage A, Tchobroutsky G. Pectin efficacy in insulin-treated diabetics assessed by the artificial pancreas. Lancet 1980;1;8160

1979

Chaput JC, Lecomte MV, Poynard T, Buffet C, Labayle D, Etienne JP. [Relationship between mean corpuscular volume, alcohol consumption, smoking habits, and alcoholic liver disease in hospitalized patients (author's transl)] Gastroenterol. Clin. Biol. 1979;3;3
Chaput JC, Labayle D, Poynard T, Rousseau C. [Utilization of vegetable dietary fibers in therapeutic gastroenterology] Journ Annu Diabetol Hotel Dieu 1979

1978

Poynard T. [Evaluation of diagnostic methods. Application to the diagnosis of benign or malignant colonic tumours (author's transl)] Nouv Presse Med 1978;7;23

1977

Poynard T, Chaput JC, Labayle D. [Intestinal functional disorders: review of the literature] Gastroenterol. Clin. Biol. 1977;1;8-9

Back to page of Poynard, Thierry.

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.